Selected research
Industry Research
Acetaminophen-Opioid Combination Industry Research Report 2026
Market perspective
The global Acetaminophen-Opioid Combination market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Acetaminophen-Opioid Combination market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Acetaminophen-Opioid Combination market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Acetaminophen-Opioid Combination market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Acetaminophen-Opioid Combination include AstraZeneca, Endo Pharmaceuticals, Grünenthal, Hamilton Kent., Laboratoire Riva, Mallinckrodt Pharmaceuticals, Purdue Pharmaceuticals, Trio Remedies and Johnson & Johnson, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Acetaminophen-Opioid Combination market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acetaminophen-Opioid Combination.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acetaminophen-Opioid Combination Market by Company
AstraZeneca
Endo Pharmaceuticals
Grünenthal
Hamilton Kent.
Laboratoire Riva
Mallinckrodt Pharmaceuticals
Purdue Pharmaceuticals
Trio Remedies
Johnson & Johnson
Teva Pharmaceutical
Abbott
Acetaminophen-Opioid Combination Segment by Type
Tramadol/Acetaminophen
Hydrocodone/Acetaminophen
Oxycodone/Acetaminophen
Codeine/Acetaminophen
Others
Acetaminophen-Opioid Combination Segment by Application
Acute Pain
Chronic Pain
Others
Acetaminophen-Opioid Combination Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acetaminophen-Opioid Combination market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acetaminophen-Opioid Combination and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acetaminophen-Opioid Combination.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Acetaminophen-Opioid Combination companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tramadol/Acetaminophen
- Hydrocodone/Acetaminophen
- Oxycodone/Acetaminophen
- Codeine/Acetaminophen
- Others
Applications
- Acute Pain
- Chronic Pain
- Others
Companies covered
- AstraZeneca
- Endo Pharmaceuticals
- Grünenthal
- Hamilton Kent.
- Laboratoire Riva
- Mallinckrodt Pharmaceuticals
- Purdue Pharmaceuticals
- Trio Remedies
- Johnson & Johnson
- Teva Pharmaceutical
- Abbott
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Acetaminophen-Opioid Combination by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tramadol/Acetaminophen
- 2.2.3 Hydrocodone/Acetaminophen
- 2.2.4 Oxycodone/Acetaminophen
- 2.2.5 Codeine/Acetaminophen
- 2.2.6 Others
- 2.3 Acetaminophen-Opioid Combination by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Acute Pain
- 2.3.3 Chronic Pain
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Acetaminophen-Opioid Combination Breakdown Data by Type
- 3.1 Global Acetaminophen-Opioid Combination Historic Market Size by Type (2021-2026)
- 3.2 Global Acetaminophen-Opioid Combination Forecasted Market Size by Type (2027-2032)
4 Acetaminophen-Opioid Combination Breakdown Data by Application
- 4.1 Global Acetaminophen-Opioid Combination Historic Market Size by Application (2021-2026)
- 4.2 Global Acetaminophen-Opioid Combination Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Acetaminophen-Opioid Combination Market Perspective (2021-2032)
- 5.2 Global Acetaminophen-Opioid Combination Growth Trends by Region
- 5.2.1 Global Acetaminophen-Opioid Combination Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Acetaminophen-Opioid Combination Historic Market Size by Region (2021-2026)
- 5.2.3 Acetaminophen-Opioid Combination Forecasted Market Size by Region (2027-2032)
- 5.3 Acetaminophen-Opioid Combination Market Dynamics
- 5.3.1 Acetaminophen-Opioid Combination Industry Trends
- 5.3.2 Acetaminophen-Opioid Combination Market Drivers
- 5.3.3 Acetaminophen-Opioid Combination Market Challenges
- 5.3.4 Acetaminophen-Opioid Combination Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Acetaminophen-Opioid Combination Players by Revenue
- 6.1.1 Global Top Acetaminophen-Opioid Combination Players by Revenue (2021-2026)
- 6.1.2 Global Acetaminophen-Opioid Combination Revenue Market Share by Players (2021-2026)
- 6.2 Global Acetaminophen-Opioid Combination Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Acetaminophen-Opioid Combination Head Office and Area Served
- 6.4 Global Acetaminophen-Opioid Combination Players, Product Type & Application
- 6.5 Global Acetaminophen-Opioid Combination Manufacturers Established Date
- 6.6 Global Acetaminophen-Opioid Combination Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Acetaminophen-Opioid Combination Market Size (2021-2032)
- 7.2 North America Acetaminophen-Opioid Combination Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Acetaminophen-Opioid Combination Market Size by Country (2021-2026)
- 7.4 North America Acetaminophen-Opioid Combination Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Acetaminophen-Opioid Combination Market Size (2021-2032)
- 8.2 Europe Acetaminophen-Opioid Combination Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Acetaminophen-Opioid Combination Market Size by Country (2021-2026)
- 8.4 Europe Acetaminophen-Opioid Combination Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Acetaminophen-Opioid Combination Market Size (2021-2032)
- 9.2 Asia-Pacific Acetaminophen-Opioid Combination Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Acetaminophen-Opioid Combination Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Acetaminophen-Opioid Combination Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Acetaminophen-Opioid Combination Market Size (2021-2032)
- 10.2 South America Acetaminophen-Opioid Combination Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Acetaminophen-Opioid Combination Market Size by Country (2021-2026)
- 10.4 South America Acetaminophen-Opioid Combination Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Acetaminophen-Opioid Combination Market Size (2021-2032)
- 11.2 Middle East & Africa Acetaminophen-Opioid Combination Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Acetaminophen-Opioid Combination Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Acetaminophen-Opioid Combination Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AstraZeneca
- 12.1.1 AstraZeneca Company Information
- 12.1.2 AstraZeneca Business Overview
- 12.1.3 AstraZeneca Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.1.4 AstraZeneca Acetaminophen-Opioid Combination Product Portfolio
- 12.1.5 AstraZeneca Recent Developments
- 12.2 Endo Pharmaceuticals
- 12.2.1 Endo Pharmaceuticals Company Information
- 12.2.2 Endo Pharmaceuticals Business Overview
- 12.2.3 Endo Pharmaceuticals Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.2.4 Endo Pharmaceuticals Acetaminophen-Opioid Combination Product Portfolio
- 12.2.5 Endo Pharmaceuticals Recent Developments
- 12.3 Grünenthal
- 12.3.1 Grünenthal Company Information
- 12.3.2 Grünenthal Business Overview
- 12.3.3 Grünenthal Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.3.4 Grünenthal Acetaminophen-Opioid Combination Product Portfolio
- 12.3.5 Grünenthal Recent Developments
- 12.4 Hamilton Kent.
- 12.4.1 Hamilton Kent. Company Information
- 12.4.2 Hamilton Kent. Business Overview
- 12.4.3 Hamilton Kent. Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.4.4 Hamilton Kent. Acetaminophen-Opioid Combination Product Portfolio
- 12.4.5 Hamilton Kent. Recent Developments
- 12.5 Laboratoire Riva
- 12.5.1 Laboratoire Riva Company Information
- 12.5.2 Laboratoire Riva Business Overview
- 12.5.3 Laboratoire Riva Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.5.4 Laboratoire Riva Acetaminophen-Opioid Combination Product Portfolio
- 12.5.5 Laboratoire Riva Recent Developments
- 12.6 Mallinckrodt Pharmaceuticals
- 12.6.1 Mallinckrodt Pharmaceuticals Company Information
- 12.6.2 Mallinckrodt Pharmaceuticals Business Overview
- 12.6.3 Mallinckrodt Pharmaceuticals Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.6.4 Mallinckrodt Pharmaceuticals Acetaminophen-Opioid Combination Product Portfolio
- 12.6.5 Mallinckrodt Pharmaceuticals Recent Developments
- 12.7 Purdue Pharmaceuticals
- 12.7.1 Purdue Pharmaceuticals Company Information
- 12.7.2 Purdue Pharmaceuticals Business Overview
- 12.7.3 Purdue Pharmaceuticals Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.7.4 Purdue Pharmaceuticals Acetaminophen-Opioid Combination Product Portfolio
- 12.7.5 Purdue Pharmaceuticals Recent Developments
- 12.8 Trio Remedies
- 12.8.1 Trio Remedies Company Information
- 12.8.2 Trio Remedies Business Overview
- 12.8.3 Trio Remedies Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.8.4 Trio Remedies Acetaminophen-Opioid Combination Product Portfolio
- 12.8.5 Trio Remedies Recent Developments
- 12.9 Johnson & Johnson
- 12.9.1 Johnson & Johnson Company Information
- 12.9.2 Johnson & Johnson Business Overview
- 12.9.3 Johnson & Johnson Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.9.4 Johnson & Johnson Acetaminophen-Opioid Combination Product Portfolio
- 12.9.5 Johnson & Johnson Recent Developments
- 12.10 Teva Pharmaceutical
- 12.10.1 Teva Pharmaceutical Company Information
- 12.10.2 Teva Pharmaceutical Business Overview
- 12.10.3 Teva Pharmaceutical Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.10.4 Teva Pharmaceutical Acetaminophen-Opioid Combination Product Portfolio
- 12.10.5 Teva Pharmaceutical Recent Developments
- 12.11 Abbott
- 12.11.1 Abbott Company Information
- 12.11.2 Abbott Business Overview
- 12.11.3 Abbott Revenue in Acetaminophen-Opioid Combination Business (2021-2026)
- 12.11.4 Abbott Acetaminophen-Opioid Combination Product Portfolio
- 12.11.5 Abbott Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst